P
Paul A. Burke
Researcher at Amgen
Publications - 37
Citations - 3843
Paul A. Burke is an academic researcher from Amgen. The author has contributed to research in topics: Gene silencing & Spray drying. The author has an hindex of 19, co-authored 37 publications receiving 3436 citations. Previous affiliations of Paul A. Burke include Merck & Co. & United States Military Academy.
Papers
More filters
Journal ArticleDOI
Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies
TL;DR: Recent advances in formulation and delivery strategies, such as the use of microsphere-based controlled-release technologies, protein modification methods that make use of polyethylene glycol and other polymers, and genetic manipulation of biopharmaceutical drugs are highlighted and discussed.
Journal ArticleDOI
Improving protein therapeutics with sustained-release formulations
Scott D. Putney,Paul A. Burke +1 more
TL;DR: Using injectable depot formulaions in which the protein is encapsulated in, and released slowly from, microspheres made of biodegradable polymers can justify commercial development of proteins that, for a variety of reasons, could not be marketed as solution formulations.
Patent
Method for fabricating polymer-based controlled-release devices
TL;DR: In this article, a method for forming polymer/drug microparticles comprising the steps of (1) forming a polymer solution/drug mixture comprising a polymer dissolved in an organic solvent and a suspended labile drug; (2) removing the solvent from the polymer solution and drug mixture, and (3) fragmenting the polymer and drug matrix at a temperature below the glass transition temperature of the polymeric matrix.
Patent
Methods for fabricating polymer-based controlled release preparations
TL;DR: In this article, an improved method of the polymer-based sustained release device comprises forming a polymer/active agent solution by mixing a polymer, a continuous phase, and an active agent.
Journal ArticleDOI
Evaluation of efficacy, biodistribution, and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment.
Marc Abrams,Martin Koser,Jessica Seitzer,Stephanie Williams,Martha A. DiPietro,Weimin Wang,Andrew W. Shaw,Xianzhi Mao,Vasant Jadhav,Joseph P. Davide,Paul A. Burke,Alan B. Sachs,Steven M. Stirdivant,Laura Sepp-Lorenzino +13 more
TL;DR: A liposomal siRNA delivery vehicle, LNP201, is characterized, which is capable of silencing an mRNA target in mouse liver by over 80%, and it is demonstrated that the glucocorticoid receptor (GR) agonist dexamethasone inhibits L NP201-induced cytokine release, inflammatory gene induction, and mitogen-activated protein kinase (MAPK) phosphorylation in multiple tissues.